|Mr. Daniel J. O'Connell M.B.A.||CEO, Pres & Director||801.62k||N/A||1971|
|Mr. Matt Zuga||CFO, Chief Bus. Officer & Corp. Sec.||679.27k||N/A||N/A|
|Dr. Eric Siemers M.D.||Chief Medical Officer||460.64k||N/A||1955|
|Mr. Russell Barton M.S.||Chief Operating Officer||N/A||N/A||1959|
|Mr. Derek M. Meisner Esq., J.D.||Chief Legal Officer||N/A||N/A||1971|
|Ms. Robyn Moxon M.A.||Mang. of Corp. & Clinical Communications||N/A||N/A||N/A|
|Ms. Julie Bockenstette||Exec. VP & Head of HR||N/A||N/A||N/A|
|Ms. Siew Tin Gan M.S.||Assistant VP & Head of Clinical Operations||N/A||N/A||N/A|
|Ms. Janice Hitchcock||VP & Head of Regulatory Affairs||N/A||N/A||N/A|
|Ms. Liean Schenck M.S.||VP & Head of CMC||N/A||N/A||N/A|
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc.’s ISS Governance QualityScore as of January 28, 2023 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 8; Compensation: 8.